Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Collin M BlakelyAnatoly UrismanMatthew A GubensClaire K MulveyGreg M AllenStephen C ShiboskiJulia K RotowTurja ChakrabartiD Lucas KerrJacqueline V AredoBianca BacaltosMegan GeeLisa TanKirk D JonesW Patrick DevineRobert C DoebeleDara L AisnerTejas PatilErin L SchenkTrever G BivonaJonathan W RiessMelissa ColemanJohannes R KratzDavid M JablonsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- phase ii
- rectal cancer
- tyrosine kinase
- clinical trial
- locally advanced
- small cell lung cancer
- lymph node
- open label
- phase iii
- squamous cell carcinoma
- wild type
- radiation therapy
- double blind
- randomized controlled trial
- replacement therapy
- combination therapy
- smoking cessation